Blog
RSS FeedPosted by Michael Wonder on 11 Jul 2019
New drugs: where did we go wrong and what can we do better?
10 July 2019 - More than half of new drugs entering the German health care system have not been shown to ...
Posted by Michael Wonder on 10 Jul 2019
Biomarker-based cancer diagnostics: German pricing regulator sets high validation and reimbursement standards for novel diagnostic methods
10 July 2019 - On 20 June 2019, for the first time, the German Federal Joint Committee (G-BA), made the resolution ...
Posted by Michael Wonder on 08 Jun 2019
UK, Germany, dissociate from WHO drug pricing resolution
8 June 2019 - The passage of a landmark resolution on improving the transparency of markets for medicines at the latest ...
Posted by Michael Wonder on 15 May 2019
Nivolumab and ipilimumab: drug combination has added benefit in advanced renal cell carcinoma
15 May 2019 - There are no serious disadvantages in terms of overall survival. ...
Posted by Michael Wonder on 02 May 2019
Apalutamide in prostate cancer: indication of significant added benefit
2 May 2019 - Study shows significant slowing of symptomatic progression. ...
Posted by Michael Wonder on 16 Apr 2019
Ribociclib in advanced breast cancer: survival benefits, but also severe side effects
15 April 2019 - In the overall view, an added benefit is not proven. ...
Posted by Michael Wonder on 26 Mar 2019
Numerous G-BA decisions on new medicines - five active substances with considerable added value
22 March 2019 - On Friday in Berlin, the Federal Joint Committee (G-BA) made numerous decisions on the extent of the ...
Posted by Michael Wonder on 05 Mar 2019
Methodological problems in the method used by IQWiG within early benefit assessment of new pharmaceuticals in Germany
5 March 2019 - The decision matrix applied by the IQWiG for the quantification of added benefit within the early benefit ...
Posted by Michael Wonder on 14 Feb 2019
Germany agrees on new pharmaceutical bill
13 February 2019 - On 30 January, the German government has agreed on a draft Act for more safety in ...
Posted by Michael Wonder on 03 Feb 2019
Erenumab in migraine: indication of a significant added benefit for certain patients
2 February 2019 - As a prophylaxis successful when other drug therapies are exhausted. ...
Posted by Michael Wonder on 15 Jan 2019
Progressive squamous cell carcinoma of the head and neck: pembrolizumab prolongs survival
15 January 2019 - Only a few study participants were treated in compliance with the approval, therefore the extent of ...
Posted by Michael Wonder on 14 Jan 2019
EU Health Technology Assessment needs to move up a gear, says pressure group
9 January 2019 - The European Alliance for Personalised Medicine says it may seem to everyone that the whole debate ...
Posted by Michael Wonder on 10 Jan 2019
2018 in a nutshell: new edition with facts and graphics from the IQWiG
9 January 2019 - The focus of the 33-page brochure is information, overviews and charts on "Health Technology Assessment (HTA) ...
Posted by Michael Wonder on 08 Dec 2018
AMNOG as a learning system: new study on ingenol mebutate in actinic keratosis shows added benefit
3 December 2018 - Advantage over diclofenac in complete clearance of visible lesions / unclear sustainability of treatment effect ...
Posted by Michael Wonder on 07 Dec 2018
Underuse of innovative medicines in Germany: A justification for government intervention?
6 December 2018 - The German market for innovative medicines is characterised by simultaneous underuse and overuse. ...